beta-blocker

(redirected from timolol maleate)
Also found in: Thesaurus, Medical, Encyclopedia.

be·ta-block·er

 (bā′tə-blŏk′ər, bē′-)
n.
A drug that blocks beta-receptors, thus counteracting the excitatory effects of norepinephrine and other beta-agonists released from sympathetic nerve endings. Beta-blockers are used primarily to treat angina, hypertension, arrhythmia, and migraine. Also called beta-adrenergic antagonist, beta-adrenergic blocker.

beta-blocker

n
(Pharmacology) any of a class of drugs, such as propranolol, that inhibit the activity of the nerves that are stimulated by adrenaline; they therefore decrease the contraction and speed of the heart: used in the treatment of high blood pressure and angina pectoris
Translations

beta-blocker

nBetablocker m
References in periodicals archive ?
Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model.
THE USE OF TOPICAL timolol maleate as a treatment for chronic diabetic and chronic venous ulcers showed increased wound healing compared with controls, according to the results of a prospective observational study of 60 patients.
4% Polyvinyl alcohol Timolol maleate Timolol Risk of bronchospasm 0.
Tenders are invited for Eye Drop Dorzolamide Hcl 2 Percent Plus Timolol Maleate 0.
However, the fixed combination of dorzolamide with timolol maleate, a nonselective beta blocker, proved to be more effective than dorzolamide alone, in reducing the IOP and pupil diameter (PD) in glaucomatous and healthy dogs (PLUMMER et al.
ENV515 also demonstrated an IOP lowering effect comparable to prestudy topical prostaglandin analogs (XALATAN and LUMIGAN) and in-study topical timolol maleate 0.
Timolol maleate is a [beta]1 and [beta]2 (Non-selective) adrenoceptor antagonist.
Sulfacetamide, sulfanilamide, timolol maleate, glacial acetic acid, monobasic sodium phosphate, and phosphoric acid were purchased from Sigma-Aldrich.
Pharmaceutical company Lannett Company (NYSE:LCI) reported on Thursday that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.
Deep periocular infantile capillary hemangiomas responding to topical application of timolol maleate, 0.